Draupnir Bio

Draupnir Bio is an early-stage, private biotech focused on extending the reach of targeted protein degradation beyond intracellular targets to the extracellular space, which comprises ~40% of the proteome. Its proprietary platform utilizes small molecules that engage lysosome receptors, such as sortilin, to direct disease-causing proteins for degradation, with the goal of creating oral therapies for conditions with high unmet need. Founded in 2021 and headquartered in Copenhagen with R&D in Aarhus, the company is led by an experienced team and is building a preclinical pipeline, supported by significant venture capital including a €12 million seed round in 2024.

Proprietary platform for oral small molecule degraders that engage lysosome receptors (e.g., sortilin) to target extracellular and membrane-bound proteins for lysosomal degradation.

Draupnir operates in the emerging field of extracellular targeted protein degradation, competing with other platform technologies like Lysosome-Targeting Chimeras (LYTACs) and antibody-based degraders. It differentiates through its focus on oral small molecules and specific engagement of lysosome receptors like sortilin, but faces competition from larger biotechs and pharma with substantial resources.